Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients 2017-10-16 20:16
Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes 2017-08-02 16:30
Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017 2017-05-19 14:11
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease 2017-05-08 23:08
Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease 2017-02-17 20:13
GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab 2016-12-09 23:18
Takeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions 2016-10-28 16:05
Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 2016-10-17 14:00
Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 2016-09-29 03:49
Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 2016-09-18 10:54
Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease 2016-08-02 15:19
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community 2016-07-13 16:55
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease 2016-07-05 14:14
EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care 2016-06-12 11:10
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders 2016-06-08 21:02
Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions 2016-06-07 01:09
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting 2016-05-24 00:56
More than 96 Percent of Claimants Opt-In to ACTOS Resolution Program; Takeda Expects Resolution to Become Effective Once Submission Review Completed; Takeda Stands Behind ACTOS 2015-09-14 09:49
Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2015-07-30 22:58
Takeda Regroups Singapore Operations in New, Expanded Office 2015-02-25 10:00
1 2